Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25656364 | 1.00 | BACE1 (0.41) | BACE1 | |
| SCHEMBL26312607 | 0.88 | — | — | |
| SCHEMBL24403330 | 0.87 | BACE1 (0.41) | BACE1 | |
| SCHEMBL24403208 | 0.87 | BACE1 (0.41) | BACE1 | |
| SCHEMBL24929736 | 0.87 | BACE1 (0.41) | BACE1 | |
| SCHEMBL24403233 | 0.87 | BACE1 (0.41) | BACE1 | |
| Hydrochloric Acid SCHEMBL30631308 | 0.87 | BACE1 (0.41) | BACE1 | |
| Hydrochloric Acid SCHEMBL30631305 | 0.87 | BACE1 (0.41) | BACE1 | |
| SCHEMBL26312560 | 0.87 | — | — | |
| SCHEMBL24447337 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107417-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ACE, SARS1, ACE2 | BACE1 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.